User:Apharm/sandbox

Reference

Treatment [edit]

Due to the differences in clinical presentation between atypical depression and melancholic depression, studies were conducted in the late 1900s to assess the therapeutic responsiveness of the available antidepressant pharmacotherapy in this subset of patients.

Until the 2000s, Monoamine oxidase inhibitors (MAOI), such as the original iproniazid, were thought to be of superior efficacy compared to other antidepressants for the treatment of atypical depression. Since then, numerous studies and meta analyses have provided mixed results, throwing doubt on the idea of select agent superiority for the treatment of atypical depression. Regardless of the demonstrated superiority, treatment with MAOI requires a strict dietary restrictions with tyramine-containing foods and have many undesirable adverse effects such as hypertensive crisis. For such reasons, MAOI are rarely used as the preferred agent in the setting of atypical depression. There currently do not exist robust guidelines for the treatment of atypical depression.